Table 3.

Change from baseline over time in Medical Outcome Study Short Form 36 (SF-36) domain scores

SF-36 Domain	Treatment Group	Week 8	Week 16	Week 26	End Point
Physical Functioning	Placebo	3.2 ± 0.8	3.2 ± 0.9	5.0 ± 1.0	3.6 ± 0.9
	Topiramate	4.8 ± 0.8	6.4 ± 0.9	8.3 ± 1.0	5.3 ± 0.8
		NS	p = 0.025	p = 0.023	NS
Bodily Pain	Placebo	6.2 ± 1.2	6.7 ± 1.3	6.7 ± 1.4	4.6 ± 1.2
	Topiramate	12.0 ± 1.1	14.3 ± 1.4	14.5 ± 1.4	11.5 ± 1.2
		p < 0.001	p < 0.001	p < 0.001	p < 0.001
Vitality	Placebo	1.9 ± 1.0	3.1 ± 1.0	3.9 ± 1.2	1.8 ± 1.0
	Topiramate	3.8 ± 1.0	7.9 ± 1.1	10.1 ± 1.2	5.2 ± 1.0
		NS	p = 0.008	p < 0.001	p = 0.035
General Health	Placebo	1.0 ± 0.7	0.4 ± 0.8	1.6 ± 0.9	0.8 ± 0.8
	Topiramate	3.4 ± 0.7	4.3 ± 0.9	4.5 ± 0.9	2.2 ± 0.8
		p = 0.009	p < 0.001	p = 0.027	NS
Role- Emotional	Placebo	4.5 ± 2.0	4.1 ± 2.1	6.5 ± 2.3	3.0 ± 2.0
	Topiramate	2.2 ± 2.0	8.0 ± 2.2	9.3 ± 2.3	2.3 ± 2.0
		NS	NS	NS	NS
Role- Physical	Placebo	14.4 ± 2.2	15.0 ± 2.2	15.9 ± 2.5	12.0 ± 2.1
	Topiramate	19.3 ± 2.2	26.6 ± 2.4	24.1 ± 2.5	17.9 ± 2.1
		NS	p < 0.001	p = 0.018	NS
Mental Health	Placebo	-0.2 ± 0.9	0.8 ± 0.8	0.6 ± 1.0	-0.2 ± 0.9
	Topiramate	-1.5 ± 0.9	2.9 ± 0.9	3.2 ± 1.0	-0.5 ± 0.9
		NS	NS	p = 0.034	NS
Social Functioning	Placebo	5.3 ± 1.2	7.8 ± 1.2	6.8 ± 1.3	4.8 ± 1.2
	Topiramate	4.8 ± 1.2	8.5 ± 1.3	10.8 ± 1.3	4.8 ± 1.2
		NS	NS	p = 0.010	NS
Physical Component Summary	Placebo	2.8 ± 0.4	2.8 ± 0.4	3.2 ± 0.5	2.5 ± 0.4
	Topiramate	5.1 ± 0.4	5.7 ± 0.5	5.7 ± 0.5	4.7 ± 0.4
		p < 0.001	p < 0.001	p < 0.001	p < 0.001
Mental Component Summary	Placebo	0.3 ± 0.6	0.8 ± 0.5	0.9 ± 0.6	0.1 ± 0.5
	Topiramate	-0.6 ± 0.6	1.5 ± 0.6	2.2 ± 0.6	-0.2 ± 0.5
		NS	NS	p = 0.043	NS